We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Mutant “Partners in Crime” Make Blood Cancer Deadlier

News   Oct 03, 2019 | Original story from Cold Spring Harbor Laboratory

 
Mutant “Partners in Crime” Make Blood Cancer Deadlier

In AML, defective blood cells (stained purple) are present. When the cells have a double mutation of both the IDH2 and SRSF2 genes (bottom right), the number of defective cells rises considerably, indicating a more lethal disease. Credit: Krainer lab/CSHL, 2019

 
 
Advertisement
 

RELATED ARTICLES

System Developed To Predict Tumor Response to Different Treatments

News

Cancer driver genes are those with mutations that are essential for tumour development and spread. Scientists from the Structural Bioinformatics and Network Biology (SBNB) Laboratory at IRB Barcelona have developed a computational pipeline that predicts tumour response to different cancer treatments.

READ MORE

Team Identifies a Driver of Cancer Drug Resistance

News

Patients with BRCA1/2 mutations are at higher risk for breast, ovarian and prostate cancers and, in many cases, resistant to lifesaving drugs. Scientists at The University of Texas at Austin and Ajou University in South Korea have identified a driver of the drug resistance that can make a significant difference for patients with these cancers.

READ MORE

Insights Into Therapeutic Mechanisms of Cancer Drug Pomalidomide

News

Researchers report novel findings concerning the therapeutic mechanisms of pomalidomide. They showed that pomalidomide causes the breakdown of a protein called ARID2. ARID2 promotes the "expression" of genes that are critical for the growth of multiple myeloma cells, so breaking down ARID2 is harmful to the cancer cells and beneficial to patients.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE